Antagonistic Effects of OPC-14597, a Novel Antipsychotic Drug, on Quinpirole- and (-)-Sulpiride-induced Changes in Evoked Dopamine Release in Rat Striatal Slices

• Published in: Journal of pharmacy and pharmacology 1997-02, Vol.49 (2), p.206-208
• Main Authors: YAMADA, SHIGETO, HARANO, MUTSUO, YOKOO, HIDEYASU, TANAKA, MASATOSHI
• Format: Article
• Language: English
• Subjects: Animals; Antipsychotic Agents - pharmacology; Aripiprazole; Biological and medical sciences; Dopamine - metabolism; Dopamine Agents - pharmacology; Electric Stimulation; In Vitro Techniques; Male; Medical sciences; Neostriatum - drug effects; Neostriatum - metabolism; Neuropharmacology; Pharmacology. Drug treatments; Piperazines - pharmacology; Psycholeptics: tranquillizer, neuroleptic; Psychology. Psychoanalysis. Psychiatry; Psychopharmacology; Quinolones - pharmacology; Quinpirole - antagonists & inhibitors; Rats; Rats, Wistar; Sulpiride - antagonists & inhibitors
• ISSN: 0022-3573; 2042-7158
• DOI: 10.1111/j.2042-7158.1997.tb06780.x

The effects of a newly synthesized quinolinone derivative, 7‐{4‐(4‐(2,3‐dichlorophenyl)‐1‐piperazinyl) butoxy}‐3,4‐dihydro‐2‐(1H)‐quinolinone (OPC‐14597), a novel antipsychotic drug, on electrically evoked dopamine release in rat striatal slices were investigated. OPC‐14597 (0.1–10 μm) had no effect on the dopamine release evoked in the striatal slices. The decrease induced by quinpirole, a dopamine receptor agonist, in evoked dopamine release was attenuated by supervision with OPC‐14597 (1 and 10 μm) which by itself had no effect on evoked dopamine release. The increase induced by (–)‐sulpiride, a dopamine receptor antagonist, in evoked dopamine release was, moreover, also attenuated by 1 and 10 μm OPC‐14597. These findings indicate that OPC‐14597 antagonizes both dopamine agonist‐ and antagonist‐induced changes in evoked dopamine release in striatal slices in rats.